Clinical trials for new "breakthrough" in dengue treatment put to a halt
Tests considered 'highly irregular,' according to the DOH
The Department of Health (DOH) has released an official statement regarding the controversial anti-dengue/malaria drug ActRx Triact on Monday. According the The Philippine Inquirer, the Office of the Secretary under acting Secretary Janette Garin said that those who are behind the clinical trials around the country should be held accountable for this issue.
"In not following and complying with basic protocol of scientific experiments using human subjects, the researchers are endangering the lives of the Filipino people who were given ActRx Triact without accountability and transparency," said the statement from the DOH.
Aside from the lack of scientific studies on the drug’s components, the DOH also learned that the trials did not comply with the International Conference on Harmonization Guidelines for Good Clinical Practice.
For more on this story, log on to Inquirer.net.